font size
Your healthcare professional will prepare a dose of the Moderna Covid-19 vaccine.
Simon Mina / AFP via Getty Images
Covid-19 Vaccine Maker Share
Moderna
When
BioNTech
Jumped on Monday in the news that the number of cases of Covid-19 has increased in China and the story of the fourth booster round has increased in the United States.
The share of Moderna (ticker: MRNA) increased by 14.8% and the share of BioNTech (BNTX) increased by 15%.
Pfizer
(PFE) increased by 3.9%.
The move reflects a similar buy sprinkle last Wednesday when Moderna’s share price rose 10.2% and BioNTech’s share price surged 9.4%.
Moderna’s share price has fallen sharply this year, from the closing price of $ 253.98 on the last trading day of 2021 to the recent $ 157.47. Barron’s As I wrote last week, recent rallies may suggest a change in investor sentiment towards stocks.
As the pandemic environment eases and investors flee the company in the uncertainty of transition, Moderna faces the major challenge of competing with more established vaccine makers.
But recent news could regain investor confidence that the Covid-19 vaccine market will not decline rapidly.
In China, major cities, including Shenzhen, have been blocked in a new outbreak. According to the New York Times data tracker, the average daily number of new cases in China has increased by more than 450% in the last two weeks.
Cases have also increased slightly in the United Kingdom and elsewhere in Europe, as closures have become easier and the Omicron subvariant known as BA.2 has overtaken the original version of the variant.
Meanwhile, in the United States, Pfizer CEO Albert Bourla noted comments on CBS’s Sunday show Face the Nation on Monday, adding the company’s Covid-19 vaccine for the fourth time. He said the inoculation was “necessary”.
Bula made similar comments last week, but received widespread attention on Monday, further raising expectations for the next round of Covid-19 boosters in the United States.
In a note at noon on Monday, Jeffreys analyst Michael Yi said new cases in China would not increase orders for Modana’s vaccine because China uses domestic vaccines. Stated.
Still, the increase in cases could raise investor expectations that more countries will buy Moderna’s Covid-19 vaccine in 2022 or 2023, he wrote.
In February, Moderna CEO Stephane Bancel said: Barron’s The United States has not yet purchased the Covid-19 vaccine from the company in 2022 and will need to sign a new contract if there is a booster campaign this fall.
“Conclusion,” Yee wrote on Monday. “Although the outbreak in Asia is due to Omicron and it is unlikely that China will sign a contract with MRNA, the COVID newsflow should take time to resolve the pandemic and benefit the world and stocks. . “
Write a letter to Josh Nathan-Kazis (josh.nathan-kazis@barrons.com).
..
